| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
The compound has no biological target; it is a synthetic intermediate. Peptides containing D-Glu residues (the D-enantiomer of glutamic acid) are resistant to proteolytic degradation and can be used to improve peptide stability in vivo. Derivatives of this compound (e.g., adamant-1-yl tripeptide) have immunostimulatory activity. It is also used in the synthesis of peptide-based therapeutics and peptidomimetics.
|
|---|---|
| ln Vitro |
Not applicable; the compound is a building block, not directly active. The final peptide products may have various biological activities (e.g., immunostimulatory, antibacterial, or anti-inflammatory). For example, an adamant-1-yl tripeptide synthesized from Boc-D-Glu-OtBu can activate immune cells and stimulate cytokine production.
|
| ln Vivo |
Not applicable; the building block is not administered. The final peptide may be evaluated in animal models for efficacy (e.g., immune stimulation, cancer therapy).
|
| Enzyme Assay |
Not applicable; the compound is used in peptide synthesis, not in binding assays. For quality control, purity is assessed by HPLC (>98%). The compound is characterized by ¹H NMR (Boc: 1.44 ppm, tBu: 1.47 ppm, glutamic acid side chain CH2CH2 at 2.2-2.5 ppm), ¹3C NMR, and mass spectrometry (m/z 290 [M+H]+). Specific rotation: [alpha]2⁵ᴅ = -19.0deg (c=1, DMF). For SPPS, the Boc group is removed with 50% TFA in DCM (1-2 h), and the tert-butyl ester is removed with 95% TFA (2-4 h) or with TFA/TIS/H2O (95:2.5:2.5). Selective deprotection of the N-terminal Boc is possible without affecting the side chain tBu ester. The compound is soluble in DCM, DMF, and DMSO.
|
| Cell Assay |
Not applicable; used in chemical synthesis, not in cell-based assays. The final peptide may be tested in cells for immunostimulatory activity (e.g., cytokine production in PBMCs, activation of dendritic cells).
|
| Animal Protocol |
Not applicable; the building block is not administered to animals. The final peptide is evaluated in animal models for efficacy (e.g., vaccine adjuvants, anti-cancer therapy).
|
| ADME/Pharmacokinetics |
Not applicable; not intended for in vivo administration.
|
| Toxicity/Toxicokinetics |
Low toxicity. May cause skin and eye irritation. Use PPE. Not a drug.
|
| References | |
| Additional Infomation |
Boc-D-Glu-OtBu is a research-grade amino acid derivative for solid-phase peptide synthesis. It is not an FDA-approved drug. The D-enantiomer of glutamic acid confers proteolytic stability to peptides, making this building block valuable for the synthesis of peptide-based therapeutics, immunostimulatory peptides, and peptidomimetics. For research use only.
|
| Molecular Formula |
C14H25NO6
|
|---|---|
| Molecular Weight |
303.35
|
| Exact Mass |
303.168
|
| CAS # |
73872-71-6
|
| PubChem CID |
7018746
|
| Appearance |
White to off-white solid powder
|
| Density |
1.1±0.1 g/cm3
|
| Boiling Point |
449.8±40.0 °C at 760 mmHg
|
| Flash Point |
225.8±27.3 °C
|
| Vapour Pressure |
0.0±2.3 mmHg at 25°C
|
| Index of Refraction |
1.47
|
| LogP |
2.82
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
9
|
| Heavy Atom Count |
21
|
| Complexity |
391
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
[H][C@](CCC(O)=O)(NC(=O)OC(C)(C)C)C(=O)OC(C)(C)C
|
| InChi Key |
YMOYURYWGUWMFM-SECBINFHSA-N
|
| InChi Code |
InChI=1S/C14H25NO6/c1-13(2,3)20-11(18)9(7-8-10(16)17)15-12(19)21-14(4,5)6/h9H,7-8H2,1-6H3,(H,15,19)(H,16,17)/t9-/m1/s1
|
| Chemical Name |
(4R)-5-[(2-methylpropan-2-yl)oxy]-4-[(2-methylpropan-2-yl)oxycarbonylamino]-5-oxopentanoic acid
|
| Synonyms |
N-Boc-D-glutaMic acid 1-tert-butyl ester
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.2965 mL | 16.4826 mL | 32.9652 mL | |
| 5 mM | 0.6593 mL | 3.2965 mL | 6.5930 mL | |
| 10 mM | 0.3297 mL | 1.6483 mL | 3.2965 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
